Related Experiment Videos
Antiendotoxin therapies for septic shock
1Critical Care Department, Children's National Medical Center, Washington, D.C.
Abstract:
Gram-negative shock is thought to result primarily from the effects of endotoxin, a component of the bacterial outer membrane. Accordingly, therapies aimed at inhibiting, neutralizing, or clearing endotoxin have been extensively explored. Despite over 30 years of research, no antiendotoxin approach to the treatment of human septic shock is of proven benefit. In recent randomized clinical trials of monoclonal antibodies against endotoxin, therapeutic efficacy was not convincingly demonstrated. This result, however, does not eliminate the possibility that other antiendotoxin therapies may be effective. The antibodies used in these clinical trials do not appear to neutralize endotoxin in vitro and are not reproducibly protective in animal models of sepsis. Newer agents with well-defined mechanisms of antiendotoxin activity may help clarify the role of endotoxin in septic shock and prove useful therapy for some patients.
Insights
Despite decades of research, anti-endotoxin therapies for Gram-negative shock have not proven effective in humans. Newer agents may still offer therapeutic benefits for septic shock patients.
Area of Science:
- Microbiology
- Immunology
- Critical Care Medicine
Background:
- Gram-negative shock is primarily attributed to bacterial endotoxin.
- Extensive research has focused on anti-endotoxin therapies for over 30 years.
- No anti-endotoxin treatment has demonstrated proven benefit for human septic shock.
Purpose of the Study:
- To evaluate the efficacy of anti-endotoxin therapies in Gram-negative shock.
- To analyze the outcomes of recent clinical trials involving monoclonal antibodies against endotoxin.
- To explore the potential of novel anti-endotoxin agents for septic shock treatment.
Main Methods:
- Review of randomized clinical trials of monoclonal antibodies against endotoxin.
- Assessment of endotoxin neutralization in vitro.
- Evaluation of protective effects in animal models of sepsis.
Main Results:
- Recent clinical trials did not convincingly demonstrate therapeutic efficacy of monoclonal antibodies.
- Antibodies used in trials showed limited in vitro endotoxin neutralization.
- These antibodies were not consistently protective in animal sepsis models.
Conclusions:
- Current anti-endotoxin therapies, including specific monoclonal antibodies, have not proven effective for human septic shock.
- The failure of these antibodies does not preclude the success of other anti-endotoxin strategies.
- Novel agents with defined anti-endotoxin mechanisms may clarify endotoxin's role and offer future therapeutic options for septic shock.